Researchers have developed a new tool to help clinicians tailor personalized treatment plans for patients with a rare blood ...
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer ther ...
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical Products Administration (NMPA) has accepted the ...
The eighth-grader from Ventura whose heart stopped beating when he was 3 plays every Wednesday with his uncle at a small ...
Inc Class H ( (HK:1541)) just unveiled an update. ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has completed enrollment of 133 patients for the interim analysis of its Phase III clinical trial of ...
Following the presentation on April 19, 2026 from 2:00–5:00 PM PT, the poster titled “PLK1 inhibitor onvansertib potentiates the antitumor efficacy of trastuzumab deruxtecan (T-DXd) and reverses its ...
Detailed price information for Cardiff Oncology Inc (CRDF-Q) from The Globe and Mail including charting and trades.
Initial fatigue was attributed to parenting demands before marked leukocytosis prompted an ER leukemia diagnosis, reinforcing the value of reassessment and second-opinion confirmation when symptoms ...
Tyrosine kinase inhibitors (TKIs) have transformed the treatment of chronic myeloid leukemia (CML). In a study involving patients with CML in high-income countries, approximately half the patients who ...
Leukemia exemplifies the transformation of modern medicine. Once almost always fatal and poorly understood, it can now in many cases be precisely classified and treated. The path to that point was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results